Table 2 Proxy relative survival (RS) and distribution of the 27 cancer sites (GLOBOCAN 2012)
From: Global comparison of cancer outcomes: standardization and correlation with healthcare expenditures
Cancer sites | World population | Proportion (%) of new cases among different countries | ||
|---|---|---|---|---|
Proxy RS | Proportion (%) of new cases a | Range | Difference b | |
Thyroid | 0.875 | 2.1 | (0.0, 15.0) | 15.0 |
Testis | 0.800 | 0.4 | (0.0, 1.6) | 1.6 |
Corpus uteri | 0.780 | 2.3 | (0.0, 6.6) | 6.6 |
Melanoma of skin | 0.767 | 1.7 | (0.0, 11.6) | 11.6 |
Prostate | 0.745 | 7.8 | (0.6, 42.6) | 42.0 |
Breast | 0.701 | 11.9 | (2.8, 26.7) | 23.9 |
Hodgkin lymphoma | 0.667 | 0.5 | (0.0, 3.7) | 3.7 |
Bladder | 0.642 | 3.1 | (0.2, 8.6) | 8.4 |
Kidney | 0.591 | 2.4 | (0.0, 5.7) | 5.7 |
Lip, oral cavity | 0.525 | 2.1 | (0.0, 13.6) | 13.6 |
Colorectum | 0.517 | 9.7 | (0.7, 17.0) | 16.3 |
Cervix uteri | 0.514 | 3.8 | (0.5, 32.7) | 32.2 |
Non-Hodgkin lymphoma | 0.500 | 2.7 | (0.4, 12.0) | 11.6 |
Larynx | 0.476 | 1.1 | (0.0, 4.1) | 4.1 |
Nasopharynx | 0.417 | 0.6 | (0.0, 5.4) | 5.4 |
Ovary | 0.393 | 1.7 | (0.4, 5.7) | 5.3 |
Kaposi sarcoma | 0.333 | 0.3 | (0.0, 26.2) | 26.2 |
Multiple myeloma | 0.333 | 0.8 | (0.0, 2.8) | 2.8 |
Other pharynx | 0.316 | 1.0 | (0.0, 8.1) | 8.1 |
Leukaemia | 0.277 | 2.5 | (0.0, 10.0) | 10.0 |
Brain, nervous system | 0.265 | 1.8 | (0.0, 5.7) | 5.7 |
Stomach | 0.264 | 6.8 | (0.5, 20.0) | 19.5 |
Gallbladder | 0.227 | 1.3 | (0.0, 5.6) | 5.6 |
Oesophagus | 0.153 | 3.2 | (0.0, 12.8) | 12.8 |
Lung | 0.147 | 13.0 | (0.4, 25.0) | 24.6 |
Liver | 0.059 | 5.6 | (0.5, 42.7) | 42.2 |
Pancreas | 0.048 | 2.4 | (0.0, 4.7) | 4.7 |